Newly recognized strain of mice with hereditary polyuria (PUS mice) was characterized. Polyuria was inherited as a single autosomal-recessive trait. At 15 weeks, PUS mice excreted hypotonic (urine osmolality: PUS;270.8 ± 15.5 vs. cont.; 3,228.6 ± 163.6 mosm/kg) polyuria (urine volume: PUS; 25.0 ± 1.5 vs. cont.; 1.1 ± 0.1 ml/day). In PUS mice, plasma osmolality was slightly elevated as well as urinary excretion of vasopressin (AVP). Although PUS mice could concentrate urine after 24 h water deprivation, urine osmolality remained low. Blunted response to continuous infusion of dDAVP, a synthetic V2 agonist, was also observed. These in vivo studies indicated renal resistance to AVP contributed to the polyuria in this strain of mice. Microanalysis of isolated tubular segments revealed that AVP-induced cAMP accumulation in cortical collecting ducts (CCD) of PUS mice was significantly lower (60%) with or without a phosphodiesterase inhibitor, IBMX. Vasopressin induced similar cAMP accumulation in medullary ascending limbs of Henle (MAL), and medullary collecting ducts (MCD) between PUS and control mice. In CCDs, PUS mice had low basal adenylate cyclase (AdC) activity and responded less to AVP and forskolin stimulation than control mice. No difference in cyclic AMP phosphodiesterase activity was detected between control and PUS mice. These results indicate that impaired cAMP accumulation due to low AdC activity may be related to the impaired renal concentrating ability observed in this new strain of mice.

Keywords:
Hereditary polyuric mice, Resistance to vasopressin, CAMP, Adenylate cyclase, Cortical collecting ducts
1.
Knepper M, Rector FC: Urinary concentration and dilution; in Brenner BM, Rector FC (eds): The Kidney. Philadelphia, Saunders, 1996, pp 532–570.
2.
Knepper M, Burg M: Organization of nephron function. Am J Physiol 1983;244:F579–F589.
3.
Kusano E, Braun-Werness JL, Vick DJ, Keller MJ, Dousa TP: Chlorpropamide action on renal concentrating mechanism in rats with hypothalamic diabetes insipidus. J Clin Invest.1983;72:1298–1313.
4.
Margolis B, Angel J, Krenner S, Skorecki K: Vasopressin action in the kidney-overview and glomerular actions; in Cowley AW Jr, Liard JF, Ausiello DA (eds): Vasopressin. Raven Press, New York, 1988, p 97.
5.
Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S: Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361:549–552.
6.
Robertson GL: Dipsogenic diabetes insipidus: A newly recognized syndrome caused by a selective defect in the osmoregulation of thirst. Trans Assoc Am Physicians 1987;100:241–249.
7.
Holtzman EJ, Harris HW Jr, Kolkowski LF, Guay-Woodford LM, Botelho B, Ausiello DA: A molecular defect in the vasopressin V2-receptor gene causing nephrogenic diabetes insipidus. N Engl J Med 1993;328:1534–1537.
8.
Bochet DG: Nephrogenic diabetes insipidus. Am J Med 1998;105:431–442.
9.
Deen PMT, Verdijk MAJ, Knoers NVAM, Wieringa B, Monnens LAH, van Os CH, van Oost BA: Requirement of human renal water channel awuaporin-2 for vasopressin-dependent concentration of urine. Science 1994;264:92–95.
10.
Jackson BA, Edwards RM, Valtin H, Dousa TP: Cellular action of vasopressin in medullary tubules of mice with hereditary nephrogenic diabetes insipidus. J Clin Invest 1980;53:753–762.
11.
Homma S, Gapstur SM, Coffey A, Valtin H, Dousa TP: Role of cAMP-phosphodiesterase isozymes in pathogenesis of murine nephrogenic diabetes insipidus. Am J Physiol 1991;261:F345–F353.
12.
Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S: Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 1995;95:1838–1845.
13.
Frokiaer J, Marples D, Dorup J, Knepper MA: Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. Am J Physiol 1996;270(suppl):F657–F660.
14.
Marples D, Frokiaer J, Dorup J, Knepper MA, Nielsen S: Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest 1996;97:1960–1968.
15.
Christensen S, Kusano E, Yusufi ANK, Murayama N, Dousa TP: Pathogenesis of Nephrogenic diabetes insipidus due to chronic administration of lithium in rats. J Clin Invest 1985;75:1869–1879.
16.
Watabe T, Tanaka K, Kumage M, Itoh S, Kogure M, Hasegawa M, Horiuchi T, Morio M, Takeda F, Ubukata E, Miyabe S, Shimizu N: Role of endogenous arginine vasopressin in potentiating corticotropin-releasing hormone-stimulated corticotropin secretion in man. J Clin Endocrinol Metab 1988;66:1132–1137.
17.
Homma S, Kusano E, Takeda S, Murayama N, Asano Y, Dousa TP: Both beta-1 and beta-2 adrenoceptors are coupled to the cyclic AMP system in connecting tubules of rabbit nephron. J Pharmacol Exp Ther 1993;264:105–109.
18.
Valtin H, Shroeder HA: Familial hypothalamic diabetes insipidus in rats (Brattleboro strain). Am J Physiol 1964;206:425–430.
19.
Kinter LB: Water balance in the Brattleboro rat: Considerations for hormone replacement therapy. Ann NY Acad Sci 1982;394:448–463.
20.
Walker LA, Frolich JC: Dose-dependent stimulation of renal prostaglandin synthesis by deamino-8-D-arginine vasopressin in rats with hereditary diabetes insipidus. J Pharmacol Exp Ther 1981;217:87–91.
21.
Stewart A, Stewart J: Studies on syndrome of diabetes insipidus associated with oligosyndactyly in mice. Am J Physiol 1969;217:1191–1198.
22.
Naik DV, Valtin H: Hereditary vasopressin-resistant urinary concentrating defects in mice. Am J Physiol 1969;217:1183–1190.
23.
Siverstein E, Sokoloff L, Mickelsen O, Jay GE: Primary polydipsia and hydronephrosis in an inbred strain of mice. Am J Pathol 1961;38:143–159.
24.
Sokol HW, Zimmerman EA: The hormonal status of the Brattleboro rat. Ann NY Acad Sci 1982;394:535–548.
25.
Zerbe RL, Robertson GL: A comparison of plasma vasopressin measurements with standard indirect test in the differential diagnosis of polyuria. N Engl J Med 1981;305:1539–1546.
26.
Gellai M, Edwards BR, Valtin H: Urinary concentrating ability during dehydration in the absence of vasopressin. Am J Physiol 1979;237:F100–F104.
27.
Valtin H, Edwards BR: GFR and the concentration of urine in the absence of vasopressin. Berliner-Davidson re-explored. Kidney Int 1987;31:634–640.
28.
Coffey AK, O’Sullivan DJ, Homma S, Dousa TP, Valtin H: Successful, specific treatment of nephrogenic diabetes insipidus (NDI) in mice (abstract). Kidney Int 1989;35:494.
29.
Krothapalli RK, Suki WN: Functional characterization of the alpha adrenergic receptor modulating the hydroosmotic effect of vasopressin on the rabbit cortical collecting tubules. J Clin Invest 1984;73:740–749.
30.
Nonoguchi H, Sands JM, Knepper M: Atrial natriuretic factor inhibits vasopressin-stimulated osmotic water permeability in rat inner medullary collecting duct. J Clin Invest 1988;82:1383–1390.
31.
Chabardes D, Brick-Ghannam C, Montegut M, Siaume-Perez S: Effect of PGE2 and α-adrenergic agonists on AVP-dependent cAMP levels in rabbit and rat CCT. Am J Physiol 1988;255:F43–F48.
32.
Anderson RJ, Breckon R: Cytokine regulation of adenylate cyclase activity in LLC-PK1 cells. Kidney Int 1992;42:559–566.
33.
Valtin H: Genetic model of diabetes insipidus; in Windhager EE (ed): Handbook of Physiology. New York, Oxford University Press, 1992, p 1281.
34.
Kriz W, Banker L: ADH-induced changes in the epithelium of the thick ascending limb in Brattleboro rats. Ann NY Acad Sci 1982;394:424–434.
35.
Kettyle WM, Valtin H: Chemical and dimensional characterization of the renal countercurrent system in mice. Kidney Int 1972;1:135–144.
36.
Lote CJ, Snape BM: Collecting duct flow rate as a determinant of equilibration between urine and renal papilla in the rat in the presence of a maximal antidiuretic hormone concentration. J Physiol 1977;270:533–544.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.